Experimental IPF Therapies: Cotrimoxazole

Marta Ribeiro avatar

by Marta Ribeiro |

Share this article:

Share article via email

pf_experimental

Cotrimoxazole (Trisulfa-FPI) is a combination of trimethoprim and sulfamethoxazole in fixed amounts (trimethoprim 80 mg and sulfamethoxazole 400 mg) used to treat bacterial, fungal and protozoal infections. It is developed and marketed worldwide with different brand names including Septra (GlaxoSmithKline plc) and Bactrim (Hoffmann-La Roche). Being a broad spectrum antibiotic, it also finds uses in other diseases where infections are secondary. Idiopathic Pulmonary Fibrosis (IPF) is one such disease where cotrimoxazole is being used as a therapeutic option.

 

Learn more about Cotrimoxazole: http://bit.ly/1WXaS1u

Print This Page

About the Author

Marta Ribeiro avatar
Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social media, worked with several media channels, and has also worked as a freelance photographer and a graphic artist for almost 10 years.

Tags

cotrimoxazole, experimental therapies, Idiopathic pulmonary fibrosis (IPF), IPF

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums

Recent Posts


Recommended reading